1 March 2022 in Kidney International
Some patients with diabetic kidney disease (DKD) show a fast progression of kidney dysfunction and are known as a "fast decliner" (FD). Therefore, it is critical to understand pathomechanisms specific for fast decline. Here, we performed a comprehensive metabolomic analysis of patients with stage G3 DKD and identified increased urinary lysophosphatidylcholine (LPC) in fast decline. This was confirmed by quantification of urinary LPC using mass spectrometry and identified urinary LPC containing saturated fatty acids palmitic (16:0) and stearic (18:0) acids was increased in FDs. The upsurge in urinary LPC levels was correlated with a decline in estimated glomerular filtration rate after 2.5 years. To clarify a pathogenic role of LPC in FD, we studied an accelerated rat model of DKD and observed an increase in LPC (16:0) and (18:0) levels in the urine and kidney tubulointerstitium as the disease progressed. These findings suggested that local dysregulation of lipid metabolism resulted in excessive accumulation of this LPC species in the kidney. Our in vitro studies also confirmed LPC-mediated lipotoxicity in cultured proximal tubular cells. LPC induced accumulation of lipid droplets via activation of peroxisome proliferator-activated receptor-δ followed by upregulation of the lipid droplet membrane protein perilipin 2 and decreased autophagic flux, thereby inducing organelle stress and subsequent apoptosis. Thus, LPC (16:0) and (18:0) may mediate a fast progression of DKD and may serve as a target for novel therapeutic approaches.
11 June 2025 in Kidney360
Key Points: The study aims to clarify the effects of bardoxolone methyl using proteomics and metabolomics analyses of plasma and urine from The Phase 2 Study of Bardoxolone Methyl in Patients with CKD and Type 2 Diabetes. This study demonstrated the first evidence in humans that bardoxolone methyl activates an antioxidant response. Background: NF erythroid 2-related factor 2 (NRF2) is crucial for defense against oxidative stress. In The Phase 2 Study of Bardoxolone Methyl in Patients with CKD and Type 2 Diabetes, bardoxolone methyl, an NRF2 activator, was shown to increase the GFR in patients with diabetic kidney disease. Although nonclinical reports suggest that bardoxolone methyl acts mainly through NRF2-mediated antioxidant response activation, this has not been proven in clinical settings. This study assessed its effects using plasma and urine from The Phase 2 Study of Bardoxolone Methyl in Patients with CKD and Type 2 Diabetes. Methods: Patients received either bardoxolone methyl or placebo daily for 16 weeks. Urine and plasma samples were collected at baseline, after 16 weeks of dosing, and 4 weeks postdosing and were cryopreserved for an analysis. A total of 45 patients in the bardoxolone methyl group and 52 in the placebo group were subjected to proteomic and metabolic analyses. Proteomic profiling was conducted using the SOMAscan assay, whereas metabolomics analyses were performed by Human Metabolome Technologies, Inc. Results: Plasma proteomics revealed that two oxidative stress–related pathways have been significantly changed by bardoxolone methyl treatment. Among these two pathways, antioxidative proteins and proteins that enhance the antioxidative process were significantly increased. Some of these increased proteins were known to be NRF2 target proteins. Similarly, urine proteomics revealed that four pathways were changed, and antioxidative proteins that are the target proteins of NRF2 were increased. Furthermore, seven metabolites that potentiate the antioxidative effect were significantly increased in urine. Conclusions: This study demonstrated the first evidence in humans that bardoxolone methyl activates an antioxidant response.
18 February 2023 in Kidney International